...sclerosis (ALS). In early December, Biohaven Pharmaceutical Co. Ltd. (NYSE:BHVN) said the glutamate modulator troriluzole (BHV-4157...

...Ltd. (NYSE:BHVN) said it will continue its Phase II/III T2 Protect AD trial of troriluzole (BHV-4157...

...Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) reported top-line data showing that trigriluzole (BHV-4157) missed the primary...
...plans to start a Phase II/III trial of trigriluzole to treat obsessive compulsive disorder (OCD). Trigriluzole...
...a glutamate modulating agent. Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN), New Haven, Conn. Product: Trigriluzole (BHV-4157...

...Holding Co. Ltd. (NYSE:BHVN) lost $1.82 to $35.56 on Monday after reporting that trigriluzole ( BHV-4157...
...treat spinocerebellar ataxia. CEO Vlad Coric told BioCentury the company will determine next steps for trigriluzole...
...compulsive disorder (OCD). Trigriluzole is a prodrug formulation of riluzole, a glutamate modulating agent. Elizabeth S. Eaton riluzole trigriluzole Biohaven...

...with hereditary spinocerebellar ataxia in a Phase IIb/III trial evaluating once-daily 140 mg oral trigriluzole (BHV-4157...
...walk, Sheehan Disability Scale, Patient and Clinician Global Impression of Change scales, safety and pharmacokinetics. Trigriluzole...
...U.S. for spinocerebellar ataxia. Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN), New Haven, Conn. Product: Trigriluzole (BHV-4157...

...valued at $490 million. Biohaven expects data in 1Q18 from a Phase II/III trial of trigriluzole...
...CGRP) antagonist, to treat migraine. It expects data from those studies in 1Q18 as well. Chris Lieu rimegepant trigriluzole Biohaven...

...William Blair and Needham. In December, Biohaven began a Phase II/III study of trigriluzole (formerly BHV-4157...
...is a prodrug formulation of riluzole, a glutamate modulating agent. Biohaven obtained worldwide rights to trigriluzole...
...has raised more than $100 million in private funding (see BioCentury, Nov. 4, 2016) . Paul Bonanos BHV-4157 BMS-927711 Biohaven...

...BHV-4157 in about 120 patients. Biohaven Pharmaceutical Holding Co. Ltd. , New Haven, Conn. Product: BHV-4157...
...time of the 8 meter walk, safety and pharmacokinetics Status: Phase IIb/III started Milestone: NA Julian Zhu BHV-4157 Biohaven...

...and “some very interesting high-value Orphan drugs in CNS.” Of particular interest for Aisling was BHV-4157...
...pivotal data out in a couple of indications.” Coric said Biohaven also plans to study BHV-4157...

...agents. Biohaven has said it hopes to start a Phase III study by 1Q17 of BHV-4157...
...spinocerebellar ataxia. The compound has Orphan Drug designation in the U.S. in the indication. Jaime De Leon BHV-0223 BHV-4157 Biohaven...